Russell Investments Group Ltd. bought a new position in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 18,343 shares of the company's stock, valued at approximately $457,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in KMTS. Brown Advisory Inc. purchased a new stake in Kestra Medical Technologies in the 1st quarter worth approximately $13,716,000. Federated Hermes Inc. purchased a new stake in Kestra Medical Technologies in the 1st quarter worth approximately $9,968,000. Invesco Ltd. purchased a new stake in Kestra Medical Technologies in the 1st quarter worth approximately $4,984,000. TD Asset Management Inc purchased a new stake in Kestra Medical Technologies in the 1st quarter worth approximately $2,306,000. Finally, Jennison Associates LLC purchased a new stake in Kestra Medical Technologies in the 1st quarter worth approximately $1,869,000.
Wall Street Analyst Weigh In
Separately, Wells Fargo & Company reduced their target price on shares of Kestra Medical Technologies from $28.00 to $27.00 and set an "overweight" rating for the company in a report on Thursday, July 17th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $27.33.
Read Our Latest Research Report on Kestra Medical Technologies
Kestra Medical Technologies Stock Performance
NASDAQ:KMTS traded down $0.08 during midday trading on Thursday, hitting $16.88. 77,666 shares of the company traded hands, compared to its average volume of 270,223. The firm has a fifty day moving average price of $16.19. Kestra Medical Technologies, Ltd. has a 12-month low of $13.25 and a 12-month high of $26.15. The company has a debt-to-equity ratio of 0.20, a quick ratio of 6.72 and a current ratio of 6.72.
About Kestra Medical Technologies
(
Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
Read More
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
